Both include 503A compounded medication from a licensed pharmacy, APRN supervision, dosing instructions, and follow-up
Clinical trials have demonstrated meaningful metabolic and weight-loss benefits: patients lost an average of ~15% of body weight over 68 weeks, and individuals with Type 2 diabetes achieved an average hemoglobin A1c reduction from 8.3% to 6.4%
The results revealed that semaglutide led to significant improvements in heart failure symptoms, exercise ability, and weight loss compared to the placebo
Type 2 diabetes: principles of pathogenesis and therapy
With 15 years of serving the communities in Northeast Florida, the practice operates with a clear mission: A commitment to excellence in patient care
At doses ranging from 40 to 200 mg taken twice daily, the highest weight reduction achieved was up to 11.7% compared to a 1.4% weight increase in the placebo group